Skip to content

Sunshine Biopharma Inc.: 10-Q filed 2026-08-13

What Sunshine Biopharma Inc. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 43 published measures, 119 facts as tagged in accession 0001683168-26-006340.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001683168-26-006340 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sunshine Biopharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3033,632,901USD
At 2025-12-3130,079,167USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-306,094,899USD
At 2025-12-317,040,707USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3027,538,002USD
At 2026-03-3121,516,594USD
At 2025-12-3123,038,460USD
At 2025-06-3025,684,804USD
At 2025-03-3122,702,470USD
At 2024-12-3123,500,754USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,564,048USD91
2026-01-01 to 2026-06-30-2,807,917USD181
2025-04-01 to 2025-06-30-1,770,834USD91
2025-01-01 to 2025-06-30-2,950,605USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-2,990,077USD181
2025-01-01 to 2025-06-30-2,968,400USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-3012,144USD181
2025-01-01 to 2025-06-30167,490USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-309,263,687USD91
2026-01-01 to 2026-06-3017,352,452USD181
2025-04-01 to 2025-06-309,410,230USD91
2025-01-01 to 2025-06-3018,311,571USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-307,804,185USD181
2025-01-01 to 2025-06-304,023,908USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-109,638USD181
2025-01-01 to 2025-06-30-762,204USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-77,823,043USD
At 2025-12-31-75,015,126USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,365,324shares91
2026-01-01 to 2026-06-30952,435shares181
2025-04-01 to 2025-06-30449,611shares91
2025-01-01 to 2025-06-30360,465shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1.15USD/shares91
2026-01-01 to 2026-06-30-2.95USD/shares181
2025-04-01 to 2025-06-30-3.94USD/shares91
2025-01-01 to 2025-06-30-8.19USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-30-209,166USD91
2025-01-01 to 2025-06-30-249,327USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-30477,047USD
At 2025-12-31557,370USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,612,858USD91
2026-01-01 to 2026-06-30-3,008,455USD181
2025-04-01 to 2025-06-30-2,054,655USD91
2025-01-01 to 2025-06-30-3,350,405USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3030,665,427USD
At 2025-12-3126,853,581USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-305,619,079USD
At 2025-12-316,443,922USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-304,852,488USD
At 2025-12-315,664,212USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2026-06-301,841,970USD
At 2025-12-311,889,370USD
At 2024-12-313,019,717USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-304,035,360USD
At 2025-12-313,459,864USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-06-3012,121,796USD
At 2025-12-3113,472,025USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,426,682USD91
2026-01-01 to 2026-06-304,607,672USD181
2025-04-01 to 2025-06-303,422,866USD91
2025-01-01 to 2025-06-306,153,292USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,837,005USD91
2026-01-01 to 2026-06-3012,744,780USD181
2025-04-01 to 2025-06-305,987,364USD91
2025-01-01 to 2025-06-3012,158,279USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,222USD91
2026-01-01 to 2026-06-3044,946USD181
2025-04-01 to 2025-06-30196,232USD91
2025-01-01 to 2025-06-30411,509USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-302,388,516shares
At 2025-12-31490,595shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3013,748,301USD
At 2025-12-319,123,308USD
At 2025-06-3010,305,320USD
At 2024-12-319,686,529USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30106,004,591USD
At 2025-12-3198,105,404USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-658,935USD
At 2025-12-31-65,309USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-30648,457USD
At 2025-12-31778,846USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2026-06-301,007,496USD
At 2025-12-311,070,249USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-30530,449USD
At 2025-12-31512,879USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-06-301,841,970USD
At 2025-12-311,889,370USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,564,048USD91
2026-01-01 to 2026-06-30-2,807,917USD181
2025-04-01 to 2025-06-30-1,980,000USD91
2025-01-01 to 2025-06-30-3,199,932USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,879,677USD91
2026-01-01 to 2026-06-30-3,401,543USD181
2025-04-01 to 2025-06-30-686,277USD91
2025-01-01 to 2025-06-30-1,839,859USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-2,807,917USD181
2025-01-01 to 2025-06-30-2,950,605USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-304,039,540USD91
2026-01-01 to 2026-06-307,616,127USD181
2025-04-01 to 2025-06-305,477,521USD91
2025-01-01 to 2025-06-309,503,697USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2026-01-01 to 2026-06-30154,833USD181
2025-01-01 to 2025-06-30137,236USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-3048,810USD91
2026-01-01 to 2026-06-30200,538USD181
2025-04-01 to 2025-06-3074,655USD91
2025-01-01 to 2025-06-30150,473USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-300USD181
2025-01-01 to 2025-06-300USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2026-01-01 to 2026-06-300USD181
2025-01-01 to 2025-06-300USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-305,085,000USD181
2025-01-01 to 2025-06-301,828,596USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30698,211USD181
2025-01-01 to 2025-06-30-492,384USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-872,395USD181
2025-01-01 to 2025-06-301,123,909USD181

Inspect the source

Entity
Sunshine Biopharma Inc. / CIK 0001402328
Captured
2026-09-20T08:00:47.083Z
SEC response SHA-256
089eb69bd01c2bc993f5073ccdb651eba31ddb7f7ea640d657095dcd4ddd9932

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402328.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))